key: cord-0813483-ujsh19j3
authors: Rashid, Azman; Sy, Karla Therese L.; Cabrejas, Jacob M.; Nichols, Brooke E.; Bhadelia, Nahid; Murray, Eleanor J.
title: A clinician’s primer on epidemiology for COVID-19
date: 2021-02-27
journal: Med (N Y)
DOI: 10.1016/j.medj.2021.02.007
sha: 3fdc820554452da235fcfec485287899ff4bdf18
doc_id: 813483
cord_uid: ujsh19j3

The COVID-19 pandemic has resulted in a concomitant deluge of medical, biological, and epidemiologic research. Clinicians are rightly interested in incorporating the best new evidence-based practices when treating COVID-19 patients and instituting SARS-CoV-2 transmission prevention protocols. However, without sufficient background knowledge, evaluating epidemiologic studies can be challenging, and a failure to identify sources of bias could lead to poor treatment decisions. Here, we provide a brief primer on key concepts and terms related to COVID-19 epidemiology in the hopes that this information will help provide clinicians with a starting point for evaluating the emerging COVID-19 literature.

The SARS-CoV-2 virus has infected millions of people globally; there are over 2 million thousand reported deaths and almost 95 million confirmed cases of COVID-19 worldwide from January 2020 to 2021 1 . The pandemic has also spurred a huge scientific effort to understand the biology, epidemiology, and clinical treatment of the virus. Epidemiology is the study of distribution and determinants of disease states in human populations, and many epidemiological studies of SARS-CoV-2 have emerged which have contributed to a better understanding of the disease. Moreover, these epidemiological findings can inform clinical practice to improve patient outcomes. Yet, many clinicians may be unfamiliar with the basic epidemiology concepts needed to read, evaluate, and incorporate evidence-based medicine into their clinical practice, particularly as they apply to emerging infectious diseases.

In this review, we aim to elucidate common epidemiological concepts essential to understanding the COVID-19 literature, with a particular focus for clinicians. Essential epidemiological concepts will be discussed, such as the terms to define morbidity and mortality, disease progression in infected individuals, and disease transmission between individuals. We will also explore basic infectious disease modeling terms. Mathematical modeling has been beneficial in making predictions about the spread of disease and assessing intervention strategies to support population-based policy decisions. Finally, we will examine different study designs in epidemiological studies, and explore common biases, such as confounding and causality, in order to aid clinicians in critically evaluating the current and rapidly changing literature on clinical treatments for COVID-19.

We begin by reviewing some basic concepts and key terms (bolded) related to infectious disease epidemiology. See the Appendix for a Glossary of Key Terms. The case fatality rate (CFR) and the infection fatality rate (IFR) highlight the mortality of the pathogen and is a useful measure to compare outcomes across different groups and populations. The CFR is the proportion of fatal cases due to the disease among all individuals that were diagnosed with the disease in a given population 2 . There are numerous factors that influence CFR and can either increase or decrease the calculated value. In particular, the CFR can be greatly affected by the case definition and guidelines for testing access. Since these vary across jurisdictions, there is unlikely to be a single J o u r n a l P r e -p r o o f CFR value that applies universally. For SARS-CoV-2 access to testing for symptomatic and asymptomatic cases and the listed cause of death-pneumonia versus SARS-CoV-2 versus pulmonary emboli-are particularly important determinants of the CFR. Expanding upon the CFR is the idea of an IFR, which is the proportion of fatal cases due to a given pathogen among the total number of infected individuals 2 . The calculation of IFR therefore expands the total number of individuals included in the numerator and denominator to also incorporate those who were not officially diagnosed with SARS-CoV-2. Depending on the jurisdiction, this could include individuals with mild symptoms or asymptotic individuals or those with self-reported influenza-like illnesses who were unable to receive confirmatory testing. The larger denominator means that the value of the IFR is always equal to or lower than the CFR. Often, at the beginning of emerging infectious diseases outbreaks, the lack of widespread diagnostic testing can lead to overestimation of both IFR and CFR, since only the sickest patients present to care and are diagnosed. Over time, as the full range of disease is understood, these values generally tend to decrease 3 . In United States jurisdictions, a recent seroprevalence study reported a broad range of 1% to 23% for detectable SARS-CoV-2 antibodies from July to September 2020; however, there was little evidence of infection among many geographic areas 4 . Widespread access to diagnostic testing or methodic population-based surveillance testing are necessary to accurately estimate the CFR and IFR.

As mentioned above, the CFR depends heavily on the case-definition for COVID-19. There are often a multitude of disease presentations of SAS-CoV-2 across a population. To explain the average progression of a disease in infected individuals, various terms are used to classify an individuals' current display of disease including asymptomatic, paucisymptomatic, and presymptomatic, in addition to symptomatic. A classification of being asymptomatic means that the person is infected by a pathogen but has an "infection with subclinical manifestation of disease" which can be detected and confirmed via laboratory tests 5 . In a SARS-CoV-2 systematic review, the virus was estimated to infect approximately 20% of "people who become infected with SARS-CoV-2 and remained asymptomatic throughout infection" 6 , yet other studies have reported a higher estimate of 40-45% 7 . Four separate studies found evidence of a small percentage of asymptomatic individuals infecting others, yet it is hard to assess the extent of this mode of transmission 8 ; although, one study reports 6% transmission from asymptomatic individuals 9 . The classification of pre-symptomatic is similar to asymptomatic, as a presymptomatic individual has an initial asymptomatic period in their disease course that later J o u r n a l P r e -p r o o f develops into a typical symptomatic state 7, 10 . One review reports a pre-symptomatic disease proportion between 0-10% that increases in older populations and closed environments (i.e cruise ships, nursing homes) cohorts 7 , yet there can be substantial variability in this proportion detected based on when the test was performed after infection ( Figure 1 ). Presymptomatic transmission accounts for about 50% of all transmission, contributing to the worldwide pandemic spread 9, 11 . Lastly, there are individuals who display mild or non-severe symptoms and therefore choose to not engage with the healthcare system and fall beneath the threshold for detection by the system 10 For SARS-CoV-2, the median incubation period is estimated to be 5 days and ranges from 4 to 11 days 13 . This is in contrast to the latency period or the period between initial exposure and the onset of the ability to transmit the virus 14 . SARS-CoV-2's median latency period was approximately 4 days 15 and ranges from 1 to 24 days 14 . The temporal discrepencies between the latent and incubation intervals partially contribute to the difficulty in disrupting pre-symptomatic transmission. Given the variability of SARS-CoV-2's latency period, the serial interval is one useful measure for characterizing the rate of SARS-CoV-2 spread. The serial interval refers to the empirical estimate of the time from illness onset in the infector to the illness onset in the infectee. The serial interval is a non-fixed range that could shorten based on implementation of non-pharmaceutical interventions such as contact tracing and case isolation 16 .

The mean serial interval for SARS-CoV-2 was estimated to be 4 days early during the J o u r n a l P r e -p r o o f pandemic 17 and around 5 days reported in a more recent meta-analysis 18 ; this estimate is essential in understanding the timing between case generations and the overall infectivity of the pathogen 14 . The serial interval distribution can be used as a proxy for non-observable generation intervals to further estimate other epidemiological parameters such as R 0 and the infectiousness of the pathogen 16, 19 . The incongruence between the serial interval and generation intervals means that depending on which time interval is used in modeling, the R 0 can be either over or underestimated. Figure 1 outlines the clinical course of infectiousness and transmission between two individuals infected with SARS-CoV-2.

Another important concept for understanding the literature on COVID-19 cases is the idea of diagnostic test performance. In medical diagnosis, test sensitivity is the ability of a test to correctly identify those with the disease (true positive rate), whereas test specificity is the ability of the test to correctly identify those without the disease (true negative rate). Positive predictive value (PPV) is the probability that a person with a positive test result is a true positive (has disease), while the negative predictive value (NPV) is the probability that a person with a negative test result is a true negative (does not have disease) 20 . Sensitivity and specificity are characteristics of the test, while the PPV and NPV depend on disease prevalence in the population. There are tradeoffs between test performance and implementation in SARS-CoV-2 diagnostics. Reverse transcription polymerase chain reaction (RT-PCR), the current standard test for diagnosing and screening COVID-19, is both highly sensitive and highly specific. One disadvantage of RT-PCR testing is that it can remain positive for much longer than the period that the person is infectious, as it detects viral RNA (including prolonged shedding) rather than live virus 21 . Because of the delays and long turnaround times of RT-PCR testing, which can take up to or greater than 2 days, rapid antigen testing has been touted as an alternative globally, even though it is less sensitive and less specific 22 . Rapid antigen tests generally have lower sensitivity than RT-PCR, but have very high sensitivity for days with transmissable viral load 22 . Frequent antigen testing has been suggested to quickly identify infected people who are more at risk for contagious spread 23 . Additionally, rapid antigen testing has been suggested in geographic areas with unmet RT-PCR clinical testing demand. A caveat to low sensitivity tests is that people who test false negative might incorrectly think they do not have disease and may not take proper preventative measures when they may actually have the disease. Thus, a negative rapid antigen test result with accompanying symptoms warrants further RT-PCR testing 22 .

Finally, when assessing case numbers, it is important to consider the types of tests being offered because these can impact who is eligible to be included as a case. Tests can be used for either clinical and surveillance purposes, and have fundamental differences. Clinical tests are generally reserved for symptomatic people and require high sensitivity in order to provide a definitive clinical diagnosis with less testing. Surveillance tests are conducted on a routine basis for testing individuals in a population who may or may not have COVID-19 symptoms and are used to understand the current incidence of disease in a population. Given the importance of clinical testing for management of disease, the willingness to pay for a test with a higher test sensitivity may be greater. Clinical testing is therefore typically done using RT-PCR. Mass population screening, on the other hand, may only be achievable with the use of rapid antigen testing. In this instance, we may be willing to accept a lower test sensitivity at a lower cost to include mass access. In order to reduce community spread, testing regimens that will capture the most infections while they are still infectious are needed, such as rapid antigen tests 23 . Yet, one disadvantage of mass tests is the increased amount of false positives (low PPV and high NPV) in the context of low disease prevalence, such as in COVID-19 24 .

Since infectious disease can be transmitted, mathematical models need to take into account the spread of disease between individuals. There is an abundance of COVID-19 literature based on mathematical modeling, and clinicians may not be familiar with the terminology required to understand these models. We briefly describe the important parameters in infectious disease modeling. R 0 , the basic reproduction number, is the number of cases produced, on average, by an infected individual where all contacts are potentially susceptible.

This measure is usually used in the early stages of the epidemic, prior to the population gaining immunity of non-pharmaceutical interventions being implemented in the population. R 0 describes the contagiousness and transmissibility of pathogens, and is a function of contact rates among individuals, transmission probability, and number of infective individuals. Thus, R 0 estimates are not exclusively determined by the pathogen, and variability in R 0 depends on local sociobehavioral and environmental settings. The R 0 for COVID-19 is currently estimated at 2.63, and ranges from 0.4 to 4.6, but other studies have estimated R 0 to range as high as 5 or 6 13, 25 .

Another important measure is the time-varying effective reproduction number, which is called R, R e , or R t . This measure is the number of people in a population who can be infected by an individual at any specific time, as it reflects the changing levels of immunity in the population and the impact of control measures limiting transmission 26 . R 0 and R e are population averages, and some individuals may infect more people than others. This individual-level variability depends on the K or overdispersion parameter. K affects the distribution of the number of secondary transmissions, and a high K creates superspreading events, where one individual infects most of the secondary cases, and the pathogen is more likely to spread in clusters.

Evidence has slowly emerged that K is an important driver for the COVID-19 pandemic, as the disease is an overdispersed pathogen, which causes large outbreaks to occur and spread faster 27, 28 . One of the key targets of modeling papers for COVID-19 has been an assessment of herd immunity. Herd immunity is the idea that there is a threshold of infection within a population, wherein the fraction of susceptible individuals is too few to continue productive infection. Herd immunity depends on properties unique to the pathogen, such as R 0 . In general, pathogens with higher R 0 , which have greater transmissibility and are more infectious, need a larger proportion of the population immune in order to achieve herd immunity. With the establishment of herd immunity, spread of infection is limited, and there is now a benefit of reduced viral transmission to the remaining proportion of the population that have no immunity.

Assuming a R 0 of 3, models suggest the establishment of herd immunity once approximately 67% of individuals in a population have immunity to the virus 2 . This estimate, however, assumes that all individuals have equal probability of infectiousness and susceptibility. The overdispersed nature of SARS-CoV-2 would lower the number of individuals needed to be immune in order to establish herd immunity 29 .

Epidemiologic studies include not only descriptive studies of infectious disease cases or characteristics, but also assessments of treatments, vaccines or other preventive interventions for reducing morbidity and mortality from a disease. Epidemiologic studies, especially those conducted using observational data, can be complicated and require specialized knowledge to conduct and evaluate. In this final section, we elucidate some of the most common issues that J o u r n a l P r e -p r o o f can arise in these studies in the hopes that this will help clinicians understand and evaluate the COVID-19 literature.

A simple starting point for evaluating research papers is to use an existing quality evaluation tool. For observational epidemiology studies that are designed to assess preventive or treatment interventions, we recommend the ROBINS-I toolset which provides a framework to assess risk of bias in clinical studies 30 . For randomized trials, we recommend the similar ROB-2 tool from the same group. 31 

Lastly, publication bias or selective reporting bias is the tendency to submit and publish "positive", novel results that reaffirm hypothetical assumptions, rather than results that are not statistically significant or "positive". This bias distorts available scientific literature and downstream meta-analysis studies. All the aforementioned biases contribute to the internal validity of the study in determination if the knowledge gained outweighs the potential biases.

Once internal validity is established, external validity should be considered. Generalizability of a study to a broader group or situation and transportability of a study in reference to diversity and application to another nation. A study that lacks external validity fails generalizability to other COVID-19 cases having their data only sampled from suspected outpatients with milder symptoms 32 (Figure 2.1) . Early COVID-19 trials often had limited transportability as there were few international site collaborations 33 ; however, a more recent Remdesivir study had 60 trial sites in 10 different countries 34 .

The types of biases assessed by the ROB-2 and ROBINS-I tools can occur in all types of studies but each type of study design has particular challenges. We briefly review these with examples.

Randomized clinical trials (RCTs) are conducted with subjects randomly allocated into treatment and control/placebo groups. This randomization process guarantees no confounding bias at baseline for treatment assignment. Placebo groups are generally provided an inert medication with no pharmacological effects to give the patient the perception they are receiving treatment or assistance for their complaints. RCTs typically are analyzed based on intention-totreatment effect considering the initial randomization treatment, regardless of what treatment they actually received 35 . Non-adherence to treatment has a negative effect on magnitude of estimation for intention-to-treatment effect and can lead to underestimated drug efficacy or safety. When trials have non-adherence, and alternative is to calculate the per-protocol effect.

The per-protocol effect is not affected by adherence as it excludes patients who did not follow treatment regiment, disregarding randomization leading to introduced biases; estimating this effect without bias is complex and requires special statistical tools 36 . Aside from the biases listed above, another challenge for randomized trials is that a small sample size study can provide weak evidence or power to determine significant effect or type II error. clinical setting as an effort to provide some therapeutic interventions against a new disease that does not have approved or proven treatments 37 . However, these types of studies may conversely hurt both patients and society more than help as they may promote the use of therapeutics without reliable evaluation of efficacy. Open-label trials have no masking or blinding as both the doctor and patient know which treatment is being provided, possibly leading to reporting or selection bias. Clinicians may be influenced in recording data if the patient is known to have given treatment and may ask more questions about adverse effects. Additionally, the patients in these studies who know they were given the experimental treatment may report less disease symptoms. Ideally, most trials have double-blinding where both study participants and clinicians have details withheld on intervention to prevent biases to the study, yet it is difficult to enforce this for procedural based or surgical interventions.

When a treatment or exposure cannot be delivered randomly, an alternative study design is the cohort study. Cohort studies do not involve any intervention, usually following a designated study population over time with comparison of incidence rates in groups that differ in exposure levels. In addition to the biases described above, cohort studies can be subject to problems related to missing data and the table 2 fallacy. The table 2 fallacy occurs when all factors adjusted for in a model are interpreted as causal for the outcome, yet may not have direct causal effects attributed to outcome of interest. An example of this is shown in a large cohort study on factors related to COVID-associated death (Figure 2 .2) 38 . Characteristics described in the model require causal methods to explore if different characteristics lead to altered risk of death.

A second type of observational study design is the case-control design. Case-control studies involve comparing cases to a suitable control group of individuals without the disease. These studies are good for studying rare outcomes and risk factors for disease, but have some particular challenges. The most important methodological challenge for case-control studies is the use of a reasonable control group. Controls should be selected in a way that is independent of their exposure or treatment status, and should include individuals who would be eligible to be cases in J o u r n a l P r e -p r o o f the study if they had developed the disease of interest. Ideally, the cases and controls should have similar baseline charactersitics to minimize potential biases. Another potential bias that is common in case-control studies is recall bias. This can occur when participants have trouble remembering details pertinent to the study, especially when cases and controls remember different levels of details. Finally, it is important to remember that case-control studies cannot typically be used to estimate the frequency of disease occurrence. For example, in a study exploring serum antibodies in SARS-CoV-2 cases and controls, the relative risk and incidence of SARS-CoV-2 in the population cannot be estimated as the number of cases and controls are preselected for in case-control studies 39 .

Another common type of observational study is the cross-sectional study. Cross-sectional studies examine relationships between diseases and other variables of interest existing in a defined population at a particular time. The main challenge for cross-sectional studies is that temporality of cause and effect or causality generally cannot be established in these studies as prevalence, the measure of disease occurrence at a particular time, is reported rather than the period incidence reported in other types of studies where patients are followed over time. A French open-label randomized trial (Gautret et al) reported a 50-fold benefit of the HCQ and AZ treatment compared to standard care. However, this odds ratio is likely to be inflated given the study's small sample size of 42 across 3 subgroups. The lack of confidence interval with this underpowered effect estimate makes it particularly difficult to evaluate this finding.

Another trial (Barbosa et al) used a large sample size of 412 symptomatic outpatients as the treatment group, yet 224 patients who refused treatment were used as controls in the study. This likely introduces confounding, since patients who refused the treatment are likely to have different baseline and disease characteristics compared to cases. This Brazilian study focused only on suspected outpatient COVID-19 cases with milder symptoms, thus lacking generalizability to confirmed or severe disease patients The openSAFELY retrospective cohort study 40 explored factors associated with COVID-19 mortality in the UK population. Strengths of this study are its use of NHS electronic health records, the large sample size (17, 278, 392) , and depicted temporal association of increased risk of COVID-19 death with characteristics such as increased age, poor socioeconomic status, and ethnic minorities. The cohort study design allows calculation for the overall cumulative incidence of COVID-19-related death from less than 0.01% in 18-39 years to .67% and 0.44% in men and women 80 years and older. The hazards/Kaplan-Meir model presents hazard ratios for many other risk factors for COVID-19-related mortality. Yet, the study does not provide any explanation on if these characteristics are related to increased susceptibility of disease or other relationships among these risk factors.

The reader may incorrectly interpret all coefficients in the model as if they are causal, known as table 2 fallacy. Factors could have confounding or effect modification between an exposure and an outcome, no effect, or other secondary effects not directly attributed to the outcome of interest. For example, age and sex may not be causally related to disease, but are adjusted for in many epidemiological models. Causal questions, such as risk factors for disease, require causal methods.

The cohort study had 1,961,269 population records with less than one year of follow-up and 142,641 with missing demographic information excluded from the study population. Missing records and differential loss of follow-up can introduce selection bias in the analyzed sample. There could also be missing data on possible confounding factors.

Additionally, the study included suspected cases of COVID-19 that were not laboratory confirmed by testing especially in older patients in care homes. These classified cases would introduce error in the study's measurement of the outcome or misclassification bias.

Adapted from Resource 38 J o u r n a l P r e -p r o o f In a recent Washington post article, data from Carnegie Mellon's COVIDcast depicted a negative correlation with percent of people who know someone with COVID-19 symptoms and wearing masks in public. This ecological study was easy and inexpensive to perform sampling from adults using Facebook. While the authors of this review do not disagree with mask wearing, the observed correlation can only provide "hypothesisgenerating" questions and no evidence for causality. In the article, Dr. Reinhart correctly states that there can be many alternate explanations for the observed pattern such as states with worser outbreaks in earlier spring could have higher mask usage later in the year; thus temporality cannot be established. Additionally, the observed association in the graph at the state level can be erroneously interpreted to exist at the individual level, also known as ecological fallacy. At the state aggregate level, many other factors may have a role in this observed association such as adherence to other COVID-19 protection measures or potential confounders like age or population structure. The COVIDcast team did attempt to adjust for population structure by weighting the responses from Census Bureau demographic data.

Adapted from (https://www.washingtonpost.com/business/2020/10/23/pandemic-data-chart-masks/) #Epitwitter

WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease

Herd Immunity: Understanding COVID-19

The many estimates of the COVID-19 case fatality rate

Estimated SARS-CoV-2 Seroprevalence in the US as of

Proportion of asymptomatic coronavirus disease 2019: A systematic review and meta-analysis

Occurrence and transmission potential of asymptomatic and presymptomatic SARSCoV-2 infections: A living systematic review and meta-analysis

Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review

Transmission of SARS-CoV-2: implications for infection prevention precautions

Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing

Asymptomatic Transmission, the Achilles' Heel of Current Strategies to Control Covid-19

Temporal dynamics in viral shedding and transmissibility of COVID-19

Criteria for releasing COVID-19 patients from isolation

Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics

A COVID-19 epidemic model with latency period

Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2)

Serial interval of SARS-CoV-2 was shortened over time by nonpharmaceutical interventions

Serial interval of COVID-19 among publicly reported confirmed cases

Estimates of serial interval for COVID-19: A systematic review and meta-analysis

Practical considerations for measuring the effective reproductive number

SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis

Fast coronavirus tests: what they can and can't do

Rethinking Covid-19 Test Sensitivity -A Strategy for Containment

Covid-19: Screening without scrutiny, spending taxpayers' billions

Covid-19: What is the R number?

Statistical Estimation of the Reproductive Number From Case Notification Data

Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong

Estimating the overdispersion in COVID-19 transmission using outbreak sizes outside China

Individual variation in susceptibility or exposure to SARS-CoV-2 lowers the herd immunity threshold

ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions

RoB 2: A revised tool for assessing risk of bias in randomised trials

Concerns About the Special Article on Hydroxychloroquine and Azithromycin in High Risk Outpatients with COVID-19 by Dr. Harvey Risch

Deficiencies in the Designs and Interventions of COVID-19

Remdesivir for the Treatment of Covid-19 -Final Report

Intention-to-treat concept: A review

Per-Protocol Analyses of Pragmatic Trials

Evaluating Promising Investigational Medical Countermeasures: Recommendations in the Absence of Guidelines

The Quest for Timely Insights Into Covid-19 Should Not Come At the Cost of Scientific Rigor

Clinical Validity of Serum Antibodies to SARS-CoV-2 : A Case-Control Study